

Date: 24 July 2025

Ref. No.: TCPCL/SEC/2025-26/00026

To,
The General Manager,
Corporate relationship department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001
Scrip Code: 543321

The Manager,
Listing department,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G,
Bandra-Kurla Complex, Bandra(E),
Mumbai-400 051
Scrip Symbol: TATVA

Subject: Intimation under Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Dear Sir/Madam,

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "SEBI Listing Regulations"), we wish to inform you that the Board of Directors of Tatva Chintan Pharma Chem Limited (the "Company") in its meeting held today i.e. 24 July 2025 have *inter-alia*, approved and taken on record the following items:

1. Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended 30 June 2025. In this regard, please find enclosed:
 - i. Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended 30 June 2025; and
 - ii. Limited Review Report (Standalone and Consolidated) for the quarter ended 30 June 2025, issued by M/s. NDJ & Co., Chartered Accountants, (Firm Registration No. 136345W), Statutory Auditors of the Company.
2. The Board, based on the recommendation of Nomination and Remuneration Committee, has approved the re-appointment of Mr. Chintan Nitinkumar Shah (DIN: 00183618) designated as Managing Director of the Company, liable to retire by rotation, for a further period of one (1) years from 01 February 2026 to 31 January 2027 (both days inclusive), subject to approval of the Members at the ensuing Annual General Meeting of the Company.
3. The Board, based on the recommendation of Nomination and Remuneration Committee, has approved the re-appointment of Mr. Ajaykumar Mansukhlal Patel (DIN: 00183745) designated as Whole-time Director of the Company, liable to retire by rotation, for a further period of one (1) years from 01 February 2026 to 31 January 2027 (both days inclusive), subject to approval of the Members at the ensuing Annual General Meeting of the Company.
4. The Board, based on the recommendation of Nomination and Remuneration Committee, has approved the re-appointment of Mr. Shekhar Rasiklal Somani (DIN: 00183665) designated as Whole-time Director of the Company, liable to retire by rotation, for a further period of one (1) years from 01 February 2026 to 31 January 2027 (both days inclusive), subject to approval of the Members at the ensuing Annual General Meeting of the Company.
5. The Board, based on the recommendation of Nomination and Remuneration Committee, has approved the re-appointment of Mr. Subhash Ambubhai Patel (DIN: 00535221) as an Independent Director of the Company, not liable to retire by rotation, for a second term of five (5) consecutive years commencing from 27 February 2026 to 26 February 2031 (both days inclusive), subject to approval of the Members at the ensuing Annual General Meeting of the Company.

6. The Board, based on the recommendation of Nomination and Remuneration Committee, has approved the re-appointment of Mr. Manher Chimanlal Desai (DIN: 09042598) as an Independent Director of the Company, not liable to retire by rotation, for a second term of five (5) consecutive years commencing from 27 February 2026 to 26 February 2031 (both days inclusive), subject to approval of the Members at the ensuing Annual General Meeting of the Company.
7. The Board, based on the recommendation of Nomination and Remuneration Committee, has approved the re-appointment of Mrs. Avani Rajesh Umatt (DIN: 09046170) as an Independent Director of the Company, not liable to retire by rotation, for a second term of five (5) consecutive years commencing from 27 February 2026 to 26 February 2031 (both days inclusive), subject to approval of the Members at the ensuing Annual General Meeting of the Company.
8. Resignation of Mr. Ashok Bothra – Chief Financial Officer, Key Managerial Personnel and Senior Management Personnel of the Company, for reasons as mentioned in the attached resignation letter, w.e.f. the close of business hours on 30 August 2025, and the resignation letter as received from Mr. Ashok Bothra is attached herewith.

Disclosure under Regulation 30 of the SEBI Listing Regulations and SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024 for matters mentioned at Item 2 to 8 above, is enclosed herewith as “**Annexure A**”.

The above information shall be made available on the website of the Company at www.tatvachintan.com.

The Meeting commenced at 11:30 A.M. and concluded at 03:35 P.M.

Kindly take above intimation on your record and oblige.

Thanking you,

Yours faithfully,

For Tatva Chintan Pharma Chem Limited

Ishwar Nayi
Company Secretary and Compliance Officer
M. No.: A37444

Encl.: As above

Disclosure under Regulation 30 of the SEBI Listing Regulations and SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024.

Annexure A

Sr. No.	Particulars	Mr. Chintan Nitinkumar Shah (Managing Director)	Mr. Ajaykumar Mansukhlal Patel (Whole-time Director)	Mr. Shekhar Rasiklal Somani (Whole-time Director)
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Re-appointment of Mr. Chintan Nitinkumar Shah (DIN: 00183618) as Managing Director of the Company	Re-appointment of Mr. Ajaykumar Mansukhlal Patel (DIN: 00183745) as Whole-time Director of the Company	Re-appointment of Mr. Shekhar Rasiklal Somani (DIN: 00183665) as Whole-time Director of the Company
2.	Date of appointment / re-appointment / cessation (as applicable) & term of appointment / re-appointment	Date of re-appointment: 01 February 2026 Re-appointment for a further period of one (1) years from 01 February 2026 to 31 January 2027 (both days inclusive), subject to the approval of the members of the Company His present tenure as Managing Director will conclude on 31 January 2026	Date of re-appointment: 01 February 2026 Re-appointment for a further period of one (1) years from 01 February 2026 to 31 January 2027 (both days inclusive), subject to the approval of the members of the Company His present tenure as Whole-time Director will conclude on 31 January 2026	Date of re-appointment: 01 February 2026 Re-appointment for a further period of one (1) years from 01 February 2026 to 31 January 2027 (both days inclusive), subject to the approval of the members of the Company His present tenure as Whole-time Director will conclude on 31 January 2026
3.	Brief profile (in case of appointment)	Mr. Chintan Nitinkumar Shah, aged 52, is a Bachelor of Engineering (Computer Science). He is one of the founding members and promoters of Tatva Chintan Pharma Chem Limited. He joined the Company in the year 1996. He has over 29 years of experience in the manufacturing / specialty chemical industry. He holds following position in the subsidiary of the Company. Tatva Chintan USA Inc. - President and Director Tatva Chintan Europe B.V. - Board Member	Mr. Ajaykumar Mansukhlal Patel, aged 53, is a Bachelor of Engineering (Chemical). He is one of the founding members and promoters of Tatva Chintan Pharma Chem Limited. He joined the Company in the year 1996. He has over 30 years of experience in the manufacturing / specialty chemical industry. He holds following position in the subsidiary of the Company. Tatva Chintan USA Inc. - Director and Treasurer Tatva Chintan Europe B.V. - Board Member	Mr. Shekhar Rasiklal Somani, aged 51, is a Bachelor's degree in pharmacy. He is one of the founding members and promoters of Tatva Chintan Pharma Chem Limited. He joined the Company in the year 1996. He has over 29 years of experience in the manufacturing / specialty chemical industry. He holds following position in the subsidiary of the Company. Tatva Chintan USA Inc. - Director and Secretary Tatva Chintan Europe B.V. - Board Member
4.	Disclosure of Relationship between Directors (in case of appointment as a Director)	Mr. Chintan Nitinkumar Shah is not related to any of the Directors of the Company	Mr. Ajaykumar Mansukhlal Patel is not related to any of the Directors of the Company	Mr. Shekhar Rasiklal Somani is not related to any of the Directors of the Company
5.	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Ltd with ref. no. NSE/CML/2018/24, both dated 20 June 2018	Mr. Chintan Nitinkumar Shah is not debarred from holding the office of Director by virtue of any SEBI Order or any other such Authority	Mr. Ajaykumar Mansukhlal Patel is not debarred from holding the office of Director by virtue of any SEBI Order or any other such Authority	Mr. Shekhar Rasiklal Somani is not debarred from holding the office of Director by virtue of any SEBI Order or any other such Authority

Registered Office and Factory : Plot No. 502/17, G.I.D.C. Estate, Ankleshwar - 393 002, District : Bharuch, Gujarat, India.

Dahej SEZ Unit : Plot No. Z/103/F/1 & 2, SEZ Area, Part-2, Dahej - 392 130, District : Bharuch, Gujarat, India.

Corporate Office and R & D Center (DSIR Approved) : Plot No. 353, G.I.D.C., Makarpura, Vadodara - 390 010, Gujarat, India.

Telephone No. : +91 75748 48533 / 34 **Fax :** +91 265 263 8533 **E-mail :** cs@tatvachintan.com **Website :** www.tatvachintan.com

Disclosure under Regulation 30 of the SEBI Listing Regulations and SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024.

Annexure A

Sr. No.	Particulars	Mr. Subhash Ambubhai Patel (Independent Director)	Mr. Manher Chimanlal Desai (Independent Director)	Mrs. Avani Rajesh Umatt (Independent Director)
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Re-appointment of Mr. Subhash Ambubhai Patel (DIN: 00535221) as Non-Executive, Independent Director of the Company	Re-appointment of Mr. Manher Chimanlal Desai (DIN: 09042598) as Non-Executive, Independent Director of the Company	Re-appointment of Mrs. Avani Rajesh Umatt (DIN: 09046170) as Non-Executive, Independent Director of the Company
2.	Date of appointment / re-appointment / cessation (as applicable) & term of appointment / re-appointment	Date of re-appointment: 27 February 2026 Re-appointment for a second term of five (5) consecutive years commencing from 27 February 2026 to 26 February 2031 (both days inclusive), subject to the approval of the members of the Company His present tenure as Independent Director will conclude on 26 February 2026	Date of re-appointment: 27 February 2026 Re-appointment for a second term of five (5) consecutive years commencing from 27 February 2026 to 26 February 2031 (both days inclusive), subject to the approval of the members of the Company His present tenure as Independent Director will conclude on 26 February 2026	Date of re-appointment: 27 February 2026 Re-appointment for a second term of five (5) consecutive years commencing from 27 February 2026 to 26 February 2031 (both days inclusive), subject to the approval of the members of the Company Her present tenure as Independent Director will conclude on 26 February 2026
3.	Brief profile (in case of appointment)	Mr. Subhash Ambubhai Patel is Chartered Accountant by profession and a Commerce Graduate from Maharaja Sayajirao University of Baroda. He is a fellow Member of the Institute of Chartered Accountants of India and has an experience of over 32 years. He is currently serve as the managing partner at M/s. S. A. Patel & Co., Chartered Accountants. He is also a Director on the Board of Tatva Chintan USA Inc. (Wholly Owned Subsidiary) of the Company and Dreams Stock Brokers Private Limited	Mr. Manher Chimanlal Desai is a Post Graduate in Organic Chemistry and holds Doctorate in Science from the University of Mumbai. He carries rich experience in the Specialty Chemicals Industry and was previously associated with various esteemed companies such as Indian Dyestuff Industries Limited, Metrochem Industries Limited, Alaknanda Organic Limited and Heubach Colour Private Limited. He is also a Board Member of Tatva Chintan Europe B.V. (Wholly Owned Subsidiary) of the Company	Mrs. Avani Rajesh Umatt holds a master's degree in Applied Chemistry from The Maharaja Sayajirao University of Baroda and a Doctorate in Chemistry from Sardar Patel University. She has over 23 years of experience in academics, research and administration. She is currently associated with TeamLease Skills University as a Professor, Dean Academics and incharge Provost
4.	Disclosure of Relationship between Directors (in case of appointment as a Director)	Mr. Subhash Ambubhai Patel is not related to any of the Directors of the Company	Mr. Manher Chimanlal Desai is not related to any of the Directors of the Company	Mrs. Avani Rajesh Umatt is not related to any of the Directors of the Company
5.	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Ltd with ref. no. NSE/CML/2018/24, both dated 20 June 2018	Mr. Subhash Ambubhai Patel is not debarred from holding the office of Director by virtue of any SEBI Order or any other such Authority	Mr. Manher Chimanlal Desai is not debarred from holding the office of Director by virtue of any SEBI Order or any other such Authority	Mrs. Avani Rajesh Umatt is not debarred from holding the office of Director by virtue of any SEBI Order or any other such Authority

Registered Office and Factory : Plot No. 502/17, G.I.D.C. Estate, Ankleshwar - 393 002, District : Bharuch, Gujarat, India.

Dahej SEZ Unit : Plot No. Z/103/F/1 & 2, SEZ Area, Part-2, Dahej - 392 130, District : Bharuch, Gujarat, India.

Corporate Office and R & D Center (DSIR Approved) : Plot No. 353, G.I.D.C., Makarpura, Vadodara - 390 010, Gujarat, India.

Telephone No. : +91 75748 48533 / 34 **Fax :** +91 265 263 8533 **E-mail :** cs@tatvachintan.com **Website :** www.tatvachintan.com

Disclosure under Regulation 30 of the SEBI Listing Regulations and SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024.

Annexure A

Sr. No.	Particulars	Mr. Ashok Bothra (Chief Financial Officer)
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Mr. Ashok Bothra, Chief Financial Officer, Key Managerial Personnel and a Senior Management Personnel of the Company, has tendered his resignation for reasons as mentioned in the attached resignation letter.
2.	Date of appointment / re-appointment / cessation (as applicable) & term of appointment / re-appointment	Date of Cessation - Effective close of business hours on 30 August 2025.
3.	Brief profile (in case of appointment)	N.A.
4.	Disclosure of Relationship between Directors (in case of appointment as a Director)	N.A.
5.	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Ltd with ref. no. NSE/CML/2018/24, both dated 20 June 2018	N.A.

24 July 2025

To
The Board of Directors,
Tatva Chintan pharma Chem Ltd
353, GIDC Makarpura,
Vadodara- 390010

Sub: Resignation from the position of CFO

Dear Directors,

I am writing to formally resign from my position of Chief Financial Officer.

This decision has not been easy and comes after careful consideration of my personal and professional goals. Working with Tatva has been a highly enriching experience, and I am deeply grateful for the opportunities I have had to contribute to the company's growth and success.

I would like to express my sincere appreciation to the entire Board and leadership team for support and collaboration during my tenure. I am proud of what we have achieved together and I am confident that the company will continue to thrive.


As discussed, and mutually agreed, please note that the last date of my employment will be 30 August 2025. Over the coming weeks, I am committed to ensuring a smooth transition. I will work closely with Team to hand over responsibilities and provide any necessary support to facilitate continuity.

Please let me know how I can assist during this transition period. I wish Tatva, continued success and growth in the future.

With Warm Regards



Ashok Bothra



INDEPENDENT AUDITOR'S REVIEW REPORT ON THE CONSOLIDATED STATEMENT OF FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF TATVA CHINTAN PHARMA CHEM LIMITED

1. We have reviewed the accompanying Consolidated Statement of Financial Results of Tatva Chintan Pharma Chem Limited ("Holding Company") and its subsidiaries (the Holding and its subsidiaries together referred to as "the Group") for the quarter ended 30th June, 2025 ("the Statement") being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.
5. The Statement includes the results of the following entities:
 - a) Tatva Chintan Pharma Chem Limited – the Holding Company
 - b) Tatva Chintan USA Inc. – Wholly Owned Subsidiary
 - c) Tatva Chintan Europe B.V. – Wholly Owned Subsidiary



6. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For NDJ & Co.

Chartered Accountants

Firm's Registration Number: 136345W

Basant



CA Basant Chandak

Partner

Membership No.: 434585

UDIN No.: 25434585BMISZB4348

Date: 24 July 2025

Place: Vadodara



Tatva Chintan Pharma Chem Limited

CIN: L24232GJ1996PLC029894

Registered office: Plot no. 502/17, GIDC Estate, Ankleshwar, Bharuch, Gujarat – 393 002
Website : www.tatvachintan.com, E-mail : cs@tatvachintan.com, Tel. no. : +91 75748 48533

Consolidated Statement of Financial Results

for the quarter ended 30 June 2025

(Currency: Indian Rupees in million, except per share data)

Sr. No.	Particulars	Quarter ended			Year ended
		30.06.2025 (Unaudited)	31.03.2025 (Unaudited)	30.06.2024 (Unaudited)	31.03.2025 (Audited)
	Income				
1	Revenue from operations	1,168.64	1,078.64	1,054.64	3,827.14
2	Other income	11.55	7.22	11.73	23.15
3	Total income (1+2)	1,180.19	1,085.86	1,066.37	3,850.29
	Expenses				
	Cost of materials consumed	638.89	479.16	415.22	1,737.64
	Purchases of stock-in-trade	12.89	7.75	5.43	29.80
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(68.32)	89.94	149.34	221.97
	Employee benefits expense	140.86	140.48	126.95	529.16
	Finance costs	4.13	3.88	3.14	12.90
	Depreciation and amortisation expenses	89.71	72.58	66.65	276.59
	Other expenses	271.02	271.80	231.55	966.44
4	Total expenses	1,089.18	1,065.59	998.28	3,774.50
5	Profit before exceptional items and tax (3-4)	91.01	20.27	68.09	75.79
6	Exceptional items	-	-	-	-
7	Profit before tax (5-6)	91.01	20.27	68.09	75.79
	Tax expenses				
	Current tax	18.62	6.70	9.27	15.47
	Deferred tax	5.88	3.27	6.73	3.19
8	Total tax expenses	24.50	9.97	16.00	18.66
9	Profit for the period/year (7-8)	66.51	10.30	52.09	57.13
	Other comprehensive income/(expense)				
	Items that will not be reclassified to profit or loss	(0.98)	(0.80)	(0.75)	(3.06)
	Income tax relating to items that will not be reclassified to profit or loss	0.28	0.23	0.22	0.89
	Items that will be reclassified to profit or loss	6.80	1.98	10.17	9.24
	Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
10	Other comprehensive income for the period/year, net of tax	6.10	1.41	9.64	7.07
11	Total comprehensive income for the period/year (9+10)	72.61	11.71	61.73	64.20
12	Profit for the period/year attributable to:				
	- Owners of the parent	66.51	10.30	52.09	57.13
	- Non controlling interests	-	-	-	-
		66.51	10.30	52.09	57.13
13	Other comprehensive income for the period/year attributable to:				
	- Owners of the parent	6.10	1.41	9.64	7.07
	- Non controlling interests	-	-	-	-
		6.10	1.41	9.64	7.07
14	Total comprehensive income for the period/year attributable to:				
	- Owners of the parent	72.61	11.71	61.73	64.20
	- Non controlling interests	-	-	-	-
		72.61	11.71	61.73	64.20
15	Earnings per share (Face value of Rs 10/- each) (not annualised)				
	- Basic	2.84	0.44	2.23	2.44
	- Diluted	2.84	0.44	2.23	2.44
16	Paid - up equity share capital (Face value of Rs 10/- each)	233.92	233.92	233.92	233.92
17	Other equity excluding revaluation reserve				7,154.32

Notes forming part of the consolidated statement of financial results

1- 7





Tatva Chintan Pharma Chem Limited

CIN: L24232GJ1996PLC029894

Registered office: Plot no. 502/17, GIDC Estate, Ankleshwar, Bharuch, Gujarat – 393 002

Website : www.tatvachintan.com, E-mail : cs@tatvachintan.com, Tel. no.: +91 75748 48533

Notes forming part of the Consolidated Statement of Financial Results

for the quarter ended 30 June 2025

(Currency: Indian Rupees in million)

- 1 In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, this Statement of Consolidated Financial Results for the quarter ended 30 June 2025 ("Consolidated Financial Results") of Tatva Chintan Pharma Chem Limited ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group" or "the Company") has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 24 July 2025.
- 2 The Consolidated Financial Results of the Company for the quarter ended 30 June 2025, has been subjected to limited review by the statutory auditors of the Company, who has expressed an unmodified opinion.
- 3 The Consolidated Financial Results of the Company have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 4 The Company has only one reportable business segment i.e. specialty chemicals, accordingly segment disclosure is not required as per Ind AS 108 - Operating Segments.
- 5 Key numbers of Standalone Statement of Financial Results for the quarter ended 30 June 2025:

Sr. no.	Particulars	Quarter ended			Year ended
		30.06.2025 (Unaudited)	31.03.2025 (Unaudited)	30.06.2024 (Unaudited)	31.03.2025 (Audited)
1.	Total income from operations (Net)	1,091.80	1,076.48	938.08	3,664.15
2.	Net profit before tax (before exceptional items)	70.54	15.54	21.37	4.61
3.	Net profit before tax (after exceptional items)	70.54	15.54	21.37	4.61
4.	Net profit after tax	51.33	10.95	15.08	3.27
5.	Total comprehensive income	50.63	10.38	14.55	1.10

- 6 The Consolidated Financial Results of the Company shall be available on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com), where the equity shares of the Company are listed and also on Company's website www.tatvachintan.com.
- 7 Figures for the previous periods/year have been re-classified/re-arranged/re-grouped to conform to classification of current period, wherever necessary.

For and on behalf of the Board of Directors of
Tatva Chintan Pharma Chem Limited

Chintan N. Shah
Chairman and Managing Director
DIN : 00183618
Place : Vadodara, Gujarat, India
Date : 24 July 2025



INDEPENDENT AUDITOR'S REVIEW REPORT ON THE STANDALONE STATEMENT OF FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF TATVA CHINTAN PHARMA CHEM LIMITED

1. We have reviewed the accompanying Standalone Statement of Financial Results of Tatva Chintan Pharma Chem Limited ("the Company") for the quarter ended 30th June 2025 ("the Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For NDJ & Co.

Chartered Accountants

Firm's Registration Number: 136345W

Basant



CA Basant Chandak

Partner

Membership No.: 434585

UDIN No.: 25434585BMISZA3602

Date: 24 July 2025

Place: Vadodara



Tatva Chintan Pharma Chem Limited

CIN: L24232GJ1996PLC029894

Registered office: Plot no. 502/17, GIDC Estate, Ankleshwar, Bharuch, Gujarat – 393 002
Website : www.tatvachintan.com, E-mail : cs@tatvachintan.com, Tel. no.: +91 75748 48533

Standalone Statement of Financial Results

for the quarter ended 30 June 2025

(Currency: Indian Rupees in million, except per share data)

Sr. No.	Particulars	Quarter ended			Year ended
		30.06.2025 (Unaudited)	31.03.2025 (Unaudited)	30.06.2024 (Unaudited)	31.03.2025 (Audited)
	Income				
1	Revenue from operations	1,091.80	1,076.48	938.08	3,664.15
2	Other income	13.69	12.95	14.20	35.61
3	Total income (1+2)	1,105.49	1,089.43	952.28	3,699.76
	Expenses				
	Cost of materials consumed	638.89	479.16	415.22	1,737.64
	Purchases of stock-in-trade	-	-	-	-
	Changes in inventories of finished goods and work-in-progress	(89.20)	125.00	105.05	239.01
	Employee benefits expense	140.86	140.48	126.95	529.16
	Finance costs	4.13	3.88	3.14	12.90
	Depreciation and amortisation expense	89.69	72.56	66.64	276.54
	Other expenses	250.58	252.81	213.91	899.90
4	Total expenses	1,034.95	1,073.89	930.91	3,695.15
5	Profit before exceptional items and tax (3-4)	70.54	15.54	21.37	4.61
6	Exceptional items	-	-	-	-
7	Profit before tax (5-6)	70.54	15.54	21.37	4.61
	Tax expenses/(benefits)				
	Current tax	12.12	(0.14)	3.60	0.02
	Deferred tax	7.09	4.73	2.69	1.32
8	Total tax expenses	19.21	4.59	6.29	1.34
9	Profit for the period/year (7-8)	51.33	10.95	15.08	3.27
	Other comprehensive income/(expenses)				
	Items that will not be reclassified to profit or loss	(0.98)	(0.80)	(0.75)	(3.06)
	Income tax relating to items that will not be reclassified to profit or loss	0.28	0.23	0.22	0.89
10	Other comprehensive (expenses) for the period/year, net of tax	(0.70)	(0.57)	(0.53)	(2.17)
11	Total comprehensive income for the period/year (9+10)	50.63	10.38	14.55	1.10
12	Earnings per share (Face value of Rs 10/- each) (not annualised)				
	- Basic	2.19	0.47	0.64	0.14
	- Diluted	2.19	0.47	0.64	0.14
13	Paid - up equity share capital (Face value of Rs 10/- each)	233.92	233.92	233.92	233.92
14	Other equity excluding revaluation reserve				6,979.20

Notes forming part of the standalone statement of financial results

1- 6





Tatva Chintan Pharma Chem Limited

CIN: L24232GJ1996PLC029894

Registered office: Plot no. 502/17, GIDC Estate, Ankleshwar, Bharuch, Gujarat – 393 002
Website : www.tatvachintan.com, E-mail : cs@tatvachintan.com, Tel. no.: +91 75748 48533

Notes forming part of the Standalone Statement of Financial Results

for the quarter ended 30 June 2025

(Currency: Indian Rupees in million)

- 1 In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, this Statement of Standalone Financial Results for the quarter ended 30 June 2025 ("Standalone Financial Results") of Tatva Chintan Pharma Chem Limited ("the Company") has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 24 July 2025.
- 2 The Standalone Financial Results of the Company for the quarter ended 30 June 2025, has been subjected to limited review by the statutory auditors of the Company, who has expressed an unmodified opinion.
- 3 The Standalone Financial Results of the Company have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 4 The Company has only one reportable business segment i.e. specialty chemicals, accordingly segment disclosure is not required as per Ind AS 108 - Operating Segments.
- 5 The Standalone Financial Results of the Company shall be available on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com), where the equity shares of the Company are listed and also on Company's website www.tatvachintan.com.
- 6 Figures for the previous periods/year have been re-classified/re-arranged/re-grouped to conform to classification of current period, wherever necessary.

For and on behalf of the Board of Directors of
Tatva Chintan Pharma Chem Limited

Chintan N. Shah
Chairman and Managing Director
DIN : 00183618
Place : Vadodara, Gujarat, India
Date : 24 July 2025

